Philadelphia FIGHT IRB – FDA 483, Feb 2, 2017
An FDA inspection was conducted at Philadelphia FIGHT IRB, an institutional review board, from January 27 to February 2, 2017. The inspection resulted in an FDA Form 483 observation, indicating a deficiency in the organization's adherence to regulatory requirements for human subject protection. The primary issue identified was that the IRB failed to ensure that informed consent documents provided to research participants contained all necessary elements. Specifically, it was observed that thirteen FDA-regulated protocols, which commenced on or after March 7, 2012, utilized IRB-approved informed consent forms that omitted a statement mandated by U.S. law. This critical statement describes the availability of clinical trial information on ClinicalTrials.gov, reassuring participants that their identifying information would not be included. The absence of this required disclosure in numerous protocols highlights a gap in the IRB's oversight process for ensuring transparent and fully compliant informed consent. Philadelphia FIGHT IRB is now expected to provide a comprehensive response detailing corrective and preventive actions to rectify this observation and ensure full compliance with federal regulations governing informed consent for all future and ongoing clinical research.
ID · bdff36e2-6277-4d3c-bb43-d59f1e44a0a7
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.